Author: Customer Service

Hydro’s second quarter results 2026 will be released at 07:00 CEST (01:00 EDT, 06:00 BST, 05:00 UTC/GMT) on July 22, 2026. The quarterly report and presentation will be available on hydro.com at the same time as the release. President and CEO Eivind Kallevik, and Executive Vice President and CFO Trond Olaf Christophersen, will host a webinar in English at 08:30 CEST the same day. A Q&A session will follow directly after the presentation. There will be no physical presentation or press conference. To join the webinar and ask questions, please use the link to the webcast page. The webcast is powered by Zoom. No login or preregistration is required. It is also possible to join the conference using the dial-in option: Norway +47 2400 4736  London, UK +44 330 088 5830  New York, US +1 929 205 6099   Find your local number   Meeting...

 AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR15 JULY 2026 RICHEMONT POSTS STRONG START TO THE YEAR WITH SALES UP BY 20% AT CONSTANT RATES FOR ITS FIRST QUARTER ENDED 30 JUNE 2026 Highlights for the quarter ended 30 June 2026Group sales at € 6.3 billion, up by 20% at constant exchange rates and by 17% at actual exchange rates Excellent growth at Jewellery Maisons, up by 24% at constant rates; Specialist Watchmakers up by 8%, improving sequentially; solid performance at ‘Other’, including Fashion & Accessories Maisons, at +9% Strength across all regions led by local demand, with double-digit increases in the Americas, Asia Pacific, Japan and Europe at both constant and actual rates; return to growth in Middle East & Africa Sustained growth across all distribution channels, led by retail up by 24% at constant rates Continued investment...

Priority Review decision is based on phase III MAJESTY results, where Gazyva/Gazyvaro achieved significantly higher complete remission rates at two years compared to tacrolimus1 If approved, Gazyva/Gazyvaro will be the first FDA-approved therapy for primary membranous nephropathy (pMN), following global approvals in lupus nephritis and ongoing regulatory filings in lupus and idiopathic nephrotic syndrome pMN is a chronic autoimmune disease with no FDA or EMA approved therapies to date; when left untreated, up to 30% of patients progress to kidney failure over 10 years2,3Basel, 15 July 2026 – Roche (SIX: RO, ROP; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has granted Priority Review to the company’s supplemental Biologics License Application (sBLA) for Gazyva®/Gazyvaro® (obinutuzumab) for the...

EfTEN United Property Fund earned a net loss of 103 thousand euros in June and a net profit of 709 thousand euros for the first six months of the year (compared with 1,679 thousand euros in the same period last year). The net asset value (NAV) of the fund unit was 11.62 euros at the end of June, a decline of 0.4% over the month.  The June loss was primarily related to the regular valuation of the fund’s assets carried out at the end of the half-year. Across segments, mainly the valuations of office assets decreased. This was partly offset by the increase in the value of the Kristiine shopping centre — in which the fund is invested through the EfTEN Real Estate Fund 5 — and of the value of residential rental properties in the EfTEN Residential Fund.  Invego Uus-Järveküla OÜ, a development company in which the fund has an 80% stake,...

High NA EUV reaches new readiness milestone with first high-volume Logic productIntel Foundry has entered high-volume manufacturing for a subset of Intel® Core™ Ultra Series 3 processors, code-named Panther Lake, using ASML’s EXE High NA EUV technology Specific Intel 18A layers are now dual-qualified on High NA EUV in Oregon, with product shipping to customers at yields matched to the NXE platform Intel and ASML continue to closely collaborate on High NA EUV readiness with flexibility to incorporate into future nodes based on customer needsVELDHOVEN, the Netherlands, July 15, 2026 – ASML Holding N.V. (ASML) today reported that Intel Foundry is using ASML’s High NA EUV technology on the Intel 18A process node to produce a subset of its Intel® Core™ Ultra Series 3 processors. This milestone marks an important step in...

Harvest volumes Q2 2026 (1)Farming Norway 85.0 thousand tonnes  Farming Scotland 26.5 thousand tonnes  Farming Chile 17.5 thousand tonnes  Farming Canada 10.0 thousand tonnes  Farming Ireland 3.0 thousand tonnes  Farming Faroes 2.5 thousand tonnes  Farming Iceland (Arctic Fish) 5.5 thousand tonnes  Total 150.0 thousand tonnes  Harvest volumes of 150 thousand tonnes versus 133 thousand tonnes in Q2 2025 are record-high for a second quarter, equivalent to a growth of 13%. In connection with the presentation of the Q1 2026 results, Mowi guided a total harvest volume of 140k GWT for Q2 2026. Note:(1) The harvest volumes are provided in gutted weight equivalents (GWT). Additional information Operational EBIT for the Group was approx. EUR 231 million (NOK 2 543 million, EURNOK 10.99) in Q2 2026 compared with EUR 189...

MONTREAL, July 14, 2026 (GLOBE NEWSWIRE) — PREMIER HEALTH OF AMERICA INC. (TSX-V: PHA) (“Premier Health” or the “Company”) announces that, in connection with the restructuring proceedings initiated on June 23, 2026 by the Royal Bank of Canada (the “Applicant”) in its capacity as a secured creditor (the “CCAA Proceedings”) and the Court-approved restructuring transaction announced on July 3, 2026, Polar Valley Investments Limited (“Polar”) has successfully closed the acquisition of all of the equity interests in three affiliates of the Company, namely Solutions Staffing Inc. (“SSI”), Canadian Health Care Agency Ltd. (“CHCA”) and Premier Soin Nordik Inc. / Premier Health Nordik Inc. (“Nordik Québec”) (the “Transaction”). As a result of the Transaction, Polar became the sole holder of the securities of SSI, CHCA and Nordik Québec....